The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Levodopa and the Progression of Parkinson's Disease
Open accessAbstract
BACKGROUND: Despite the known benefit of levodopa in reducing the symptoms of Parkinson's disease, concern has been expressed that its use might hasten neurodegeneration. This study assessed the effect of levodopa on the rate of progression of Parkinson's disease. METHODS: In this randomized, double-blind, placebo-controlled trial, we evaluated 361 patients with early Parkinson's disease who were assigned to receive carbidopa-levodopa at a daily dose of 37.5 and 150 mg, 75 and 300 mg, or 150 and 600 mg, respectively, or a matching placebo for a period of 40 weeks, and then to undergo withdrawal of treatment for 2 weeks. The primary outcome was a change in scores on the Unified Parkinson's Disease Rating Scale (UPDRS) between baseline and 42 weeks. Neuroimaging studies of 142 subjects were performed at baseline and at week 40 to assess striatal dopamine-transporter density with the use of iodine-123-labeled 2-beta-carboxymethoxy-3-beta-(4-iodophenyl)tropane ([123I]beta-CIT) uptake. RESULTS: The severity of parkinsonism increased more in the placebo group than in all the groups receiving levodopa: the mean difference between the total score on the UPDRS at baseline and at 42 weeks was 7.8 units in the placebo group, 1.9 units in the group receiving levodopa at a dose of 150 mg daily, 1.9 in those receiving 300 mg daily, and -1.4 in those receiving 600 mg daily (P<0.001). In contrast, in a substudy of 116 patients the mean percent decline in the [123I]beta-CIT uptake was significantly greater with levodopa than placebo (-6 percent among those receiving levodopa at 150 mg daily, -4 percent in those receiving it at 300 mg daily, and -7.2 percent among those receiving it at 600 mg daily, as compared with -1.4 percent among those receiving placebo; 19 patients with no dopaminergic deficits on the baseline scans were excluded from the analysis) (P=0.036). The subjects receiving the highest dose of levodopa had significantly more dyskinesia, hypertonia, infection, headache, and nausea than those receiving placebo. CONCLUSIONS: The clinical data suggest that levodopa either slows the progression of Parkinson's disease or has a prolonged effect on the symptoms of the disease. In contrast, the neuroimaging data suggest either that levodopa accelerates the loss of nigrostriatal dopamine nerve terminals or that its pharmacologic effects modify the dopamine transporter. The potential long-term effects of levodopa on Parkinson's disease remain uncertain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Unified Parkinson's Disease Rating Scale
(2012) · SpringerReference · doi:10.1007/springerreference_184495 · Cited by 3,066
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Aromatic Amino Acids and Modification of Parkinsonism
Cotzias, G. C., Van Woert, M. H., & Schiffer, L. M. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702162760703 · Cited by 1,494
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Parkinson Study Group (2002) · JAMA · doi:10.1001/jama.287.13.1653 · Cited by 711
Riederer, P., & Wuketich, S. (1976) · Journal of Neural Transmission · doi:10.1007/bf01249445 · Cited by 577
Astrocytes protect neurons from hydrogen peroxide toxicity
Desagher, S., Glowinski, J., & Premont, J. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-08-02553.1996 · Cited by 542
Seibyl, J. P., Marchek, K. L., Quinlan, D., Sheff, K., Zoghbi, S., Zea‐Ponce, Y., Baldwin, R. M., Fussell, B., Smith, E. O., Charney, D. S., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380407 · Cited by 467
Cited by
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
The Parkinson Progression Marker Initiative (PPMI)
Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.005 · Cited by 1,892
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Parkinson’s disease: etiopathogenesis and treatment
Jankovic, J., & Tan, E. K. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322338 · Cited by 1,169
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up
Rodriguez-Oroz, M. C., Obeso, J. A., Lang, A. E., Houeto, J.-L., Pollak, P., Rehncrona, S., Kulisevsky, J., Albanese, A., Volkmann, J., Hariz, M. I., et al. (2005) · Brain · doi:10.1093/brain/awh571 · Cited by 1,057
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
“As expected, patients on any dosages of levodopa showed significant reductions in UPDRS score when compared with placebo, even 2 weeks after levodopa discontinuation.(175) This finding has been interpreted as evidence against levodopa neurotoxicity because if levodopa were toxic the UPDRS score in the levodopa groups…”
Self-citationA review of Parkinson's disease
Davie, C. A. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldn013 · Cited by 855
McKeith, I., O'Brien, J., Walker, Z., Tatsch, K., Booij, J., Darcourt, J., Padovani, A., Giubbini, R., Bonuccelli, U., Volterrani, D., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70057-1 · Cited by 716
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
Marek, K., Chowdhury, S., Siderowf, A., Lasch, S., Coffey, C. S., Caspell‐Garcia, C., Simuni, T., Jennings, D., Tanner, C. M., Trojanowski, J. Q., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.644 · Cited by 671
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
Snow, B. J., Rolfe, F. L., Lockhart, M. M., Frampton, C. M., O'Sullivan, J. D., Fung, V., Smith, R. A. J., Murphy, M. P., Taylor, K. M., & On behalf of the Protect Study Group (2010) · Movement Disorders · doi:10.1002/mds.23148 · Cited by 606
van der Kolk, N. M., de Vries, N. M., Kessels, R. P. C., Joosten, H., Zwinderman, A. H., Post, B., & Bloem, B. R. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30285-6 · Cited by 565
Ferroptosis and its potential role in the physiopathology of Parkinson’s Disease
Mahoney-Sánchez, L., Bouchaoui, H., Ayton, S., Devos, D., Duce, J. A., & Devedjian, J.-C. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101890 · Cited by 553
Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70521-x · Cited by 547
Fox, S. H., Katzenschlager, R., Lim, S., Ravina, B., Seppi, K., Coelho, M., Poewe, W., Rascol, O., Goetz, C. G., & Sampaio, C. (2011) · Movement Disorders · doi:10.1002/mds.23829 · Cited by 523
Thobois, S., Ardouin, C., Lhommee, E., Klinger, H., Lagrange, C., Xie, J., Fraix, V., Coelho Braga, M. C., Hassani, R., Kistner, A., et al. (2010) · Brain · doi:10.1093/brain/awq032 · Cited by 516
Pahwa, R., Factor, S. A., Lyons, K. E., Ondo, W. G., Gronseth, G., Bronte-Stewart, H., Hallett, M., Miyasaki, J., Stevens, J., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000215250.82576.87 · Cited by 499
The Clinically Important Difference on the Unified Parkinson's Disease Rating Scale
Shulman, L. M., Gruber-Baldini, A. L., Anderson, K. E., Fishman, P. S., Reich, S. G., & Weiner, W. J. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.295 · Cited by 494
Warren Olanow, C., Kieburtz, K., Rascol, O., Poewe, W., Schapira, A. H., Emre, M., Nissinen, H., Leinonen, M., Stocchi, F., & Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE‐PD) Investigators (2013) · Movement Disorders · doi:10.1002/mds.25364 · Cited by 484
Fabbrini, G., Brotchie, J. M., Grandas, F., Nomoto, M., & Goetz, C. G. (2007) · Movement Disorders · doi:10.1002/mds.21475 · Cited by 464
Leucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
Oxidative Stress in Parkinson's Disease: A Mechanism of Pathogenic and Therapeutic Significance
Zhou, C., Huang, Y., & Przedborski, S. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.023 · Cited by 450
Mallet, L., Schüpbach, M., N'Diaye, K., Remy, P., Bardinet, E., Czernecki, V., Welter, M.-L., Pelissolo, A., Ruberg, M., Agid, Y., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610849104 · Cited by 437
Priorities in Parkinson's disease research
Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., Piccini, P., Obeso, J. A., Rascol, O., Schapira, A., Voon, V., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3430 · Cited by 436
FDG PET in the differential diagnosis of parkinsonian disorders
Eckert, T., Barnes, A., Dhawan, V., Frucht, S., Gordon, M. F., Feigin, A. S., & Eidelberg, D. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.03.012 · Cited by 419
Progress towards therapies for disease modification in Parkinson's disease
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R., & Foltynie, T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00061-2 · Cited by 419
PD MED Collaborative Group (2014) · The Lancet · doi:10.1016/s0140-6736(14)60683-8 · Cited by 407
Venkataramana, N. K., Kumar, S. K. V., Balaraju, S., Radhakrishnan, R. C., Bansal, A., Dixit, A., Rao, D. K., Das, M., Jan, M., Gupta, P. K., et al. (2010) · Translational Research · doi:10.1016/j.trsl.2009.07.006 · Cited by 402
Changes in network activity with the progression of Parkinson's disease
Huang, C., Tang, C., Feigin, A., Lesser, M., Ma, Y., Pourfar, M., Dhawan, V., & Eidelberg, D. (2007) · Brain · doi:10.1093/brain/awm086 · Cited by 395
Quantitative wearable sensors for objective assessment of Parkinson's disease
Maetzler, W., Domingos, J., Srulijes, K., Ferreira, J. J., & Bloem, B. R. (2013) · Movement Disorders · doi:10.1002/mds.25628 · Cited by 374
Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.06.004 · Cited by 382
Stocchi, F., Rascol, O., Kieburtz, K., Poewe, W., Jankovic, J., Tolosa, E., Barone, P., Lang, A. E., & Olanow, C. W. (2010) · Annals of Neurology · doi:10.1002/ana.22060 · Cited by 374
Lang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 370
Current and experimental treatments of Parkinson disease: A guide for neuroscientists
Oertel, W., & Schulz, J. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13750 · Cited by 369
Freezing of gait: a practical approach to management
Nonnekes, J., Snijders, A. H., Nutt, J. G., Deuschl, G., Giladi, N., & Bloem, B. R. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00041-1 · Cited by 365
The basal ganglia in Parkinson's disease: Current concepts and unexplained observations
Obeso, J. A., Marin, C., Rodriguez-Oroz, C., Blesa, J., Benitez-Temiño, B., Mena-Segovia, J., Rodríguez, M., & Olanow, C. W. (2009) · Annals of Neurology · doi:10.1002/ana.21481 · Cited by 359
Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis
Tang, C. C., Poston, K. L., Eckert, T., Feigin, A., Frucht, S., Gudesblatt, M., Dhawan, V., Lesser, M., Vonsattel, J.-P., Fahn, S., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70002-8 · Cited by 354
Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease
Verschuur, C. V. M., Suwijn, S. R., Boel, J. A., Post, B., Bloem, B. R., van Hilten, J. J., van Laar, T., Tissingh, G., Munts, A. G., Deuschl, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809983 · Cited by 353
Ferreira, J. J., Katzenschlager, R., Bloem, B. R., Bonuccelli, U., Burn, D., Deuschl, G., Dietrichs, E., Fabbrini, G., Friedman, A., Kanovsky, P., et al. (2013) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03866.x · Cited by 348
Does levodopa slow or hasten the rate of progression of Parkinson’s disease?
Fahn, S., & and the Parkinson Study Group (2005) · Journal of Neurology · doi:10.1007/s00415-005-4008-5 · Cited by 347
Darcourt, J., Booij, J., Tatsch, K., Varrone, A., Vander Borght, T., Kapucu, Ö. L., Någren, K., Nobili, F., Walker, Z., & Van Laere, K. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1267-x · Cited by 346
Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts
Espay, A. J., Morgante, F., Merola, A., Fasano, A., Marsili, L., Fox, S. H., Bezard, E., Picconi, B., Calabresi, P., & Lang, A. E. (2018) · Annals of Neurology · doi:10.1002/ana.25364 · Cited by 340
Cilia, R., Akpalu, A., Sarfo, F. S., Cham, M., Amboni, M., Cereda, E., Fabbri, M., Adjei, P., Akassi, J., Bonetti, A., et al. (2014) · Brain · doi:10.1093/brain/awu195 · Cited by 339
Fahn, S. (2008) · Movement Disorders · doi:10.1002/mds.22028 · Cited by 339
Diagnosis and Initial Management of Parkinson's Disease
Nutt, J. G., & Wooten, G. F. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp043908 · Cited by 338
Mood and behavioural effects of subthalamic stimulation in Parkinson's disease
Castrioto, A., Lhommée, E., Moro, E., & Krack, P. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70294-1 · Cited by 333
Epidemiology of psychosis in Parkinson's disease
Fénelon, G., & Alves, G. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.014 · Cited by 330
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324
Levodopa for the Treatment of Parkinson's Disease
LeWitt, P. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0800326 · Cited by 312
The role of DAT-SPECT in movement disorders
Kagi, G., Bhatia, K. P., & Tolosa, E. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.157370 · Cited by 311
Progression of Parkinson's disease in the clinical phase: potential markers
Maetzler, W., Liepelt, I., & Berg, D. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70291-1 · Cited by 305
Minimal clinically important change on the unified Parkinson's disease rating scale
Schrag, A., Sampaio, C., Counsell, N., & Poewe, W. (2006) · Movement Disorders · doi:10.1002/mds.20914 · Cited by 297
Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J. P., Lees, A., Oertel, W., Poewe, W., et al. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01547.x · Cited by 297
Levodopa in Parkinson’s Disease: Current Status and Future Developments
Tambasco, N., Romoli, M., & Calabresi, P. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170510143821 · Cited by 282
Suchowersky, O., Reich, S., Perlmutter, J., Zesiewicz, T., Gronseth, G., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000215437.80053.d0 · Cited by 280
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis
Etminan, M., Gill, S. S., & Samii, A. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70097-1 · Cited by 279
Gait disorders and balance disturbances in Parkinsonʼs disease: clinical update and pathophysiology
Boonstra, T. A., van der Kooij, H., Munneke, M., & Bloem, B. R. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328305bdaf · Cited by 274
Deep Learning-Aided Parkinson's Disease Diagnosis from Handwritten Dynamics
Pereira, C. R., Weber, S. A. T., Hook, C., Rosa, G. H., & Papa, J. P. (2016) · 2016 29th SIBGRAPI Conference on Graphics, Patterns and Images (SIBGRAPI) · doi:10.1109/sibgrapi.2016.054 · Cited by 272
Monzani, E., Nicolis, S., Dell'Acqua, S., Capucciati, A., Bacchella, C., Zucca, F. A., Mosharov, E. V., Sulzer, D., Zecca, L., & Casella, L. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201811122 · Cited by 271
Clinical spectrum of levodopa‐induced complications
Aquino, C. C., & Fox, S. H. (2015) · Movement Disorders · doi:10.1002/mds.26125 · Cited by 270
The ongoing pursuit of neuroprotective therapies in Parkinson disease
Athauda, D., & Foltynie, T. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.226 · Cited by 269
Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation
Ardouin, C., Voon, V., Worbe, Y., Abouazar, N., Czernecki, V., Hosseini, H., Pelissolo, A., Moro, E., Lhommée, E., Lang, A. E., et al. (2006) · Movement Disorders · doi:10.1002/mds.21098 · Cited by 261
Blesa, J., Trigo-Damas, I., Dileone, M., del Rey, N. L.-G., Hernandez, L. F., & Obeso, J. A. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.002 · Cited by 256
Diagnosis and the premotor phase of Parkinson disease
Tolosa, E., Gaig, C., Santamaría, J., & Compta, Y. (2009) · Neurology · doi:10.1212/wnl.0b013e318198db11 · Cited by 255
Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease
Bohnen, N. I., Albm, R. L., Koeppe, R. A., Wernette, K. A., Kilbourn, M. R., Minoshima, S., & Frey, K. A. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600276 · Cited by 254
Goetz, C. G., Wuu, J., McDermott, M. P., Adler, C. H., Fahn, S., Freed, C. R., Hauser, R. A., Olanow, W. C., Shoulson, I., Tandon, P. K., et al. (2008) · Movement Disorders · doi:10.1002/mds.21894 · Cited by 253
Kordower, J. H., Herzog, C. D., Dass, B., Bakay, R. A. E., Stansell, J., Gasmi, M., & Bartus, R. T. (2006) · Annals of Neurology · doi:10.1002/ana.21032 · Cited by 252
Randomized controlled clinical trial of “virtual house calls” for Parkinson disease
Dorsey, E. R., Venkataraman, V., Grana, M. J., Bull, M. T., George, B. P., Boyd, C. M., Beck, C. A., Rajan, B., Seidmann, A., & Biglan, K. M. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.123 · Cited by 235
Levodopa in the treatment of Parkinson's disease
Schapira, A. H. V., Emre, M., Jenner, P., & Poewe, W. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02697.x · Cited by 231
Designing stem-cell-based dopamine cell replacement trials for Parkinson’s disease
TRANSEURO consortium, & Barker, R. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0507-2 · Cited by 219
Initiation of pharmacological therapy in Parkinson's disease: when, why, and how
de Bie, R. M. A., Clarke, C. E., Espay, A. J., Fox, S. H., & Lang, A. E. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30036-3 · Cited by 200
Self-citationPereira, C. R., Pereira, D. R., Rosa, G. H., Albuquerque, V. H. C., Weber, S. A. T., Hook, C., & Papa, J. P. (2018) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2018.04.001 · Cited by 209
Nanotechnology—novel therapeutics for CNS disorders
Srikanth, M., & Kessler, J. A. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.76 · Cited by 198
Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease
Müller, T. (2015) · Drugs · doi:10.1007/s40265-014-0343-0 · Cited by 190
Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia
Jarraya, B., Boulet, S., Scott Ralph, G., Jan, C., Bonvento, G., Azzouz, M., Miskin, J. E., Shin, M., Delzescaux, T., Drouot, X., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000130 · Cited by 186
Christine, C. W., Bankiewicz, K. S., Van Laar, A. D., Richardson, R. M., Ravina, B., Kells, A. P., Boot, B., Martin, A. J., Nutt, J., Thompson, M. E., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25450 · Cited by 167
Wearable sensor-based objective assessment of motor symptoms in Parkinson’s disease
Ossig, C., Antonini, A., Buhmann, C., Classen, J., Csoti, I., Falkenburger, B., Schwarz, M., Winkler, J., & Storch, A. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-015-1439-8 · Cited by 164
Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features
Ray Chaudhuri, K., Poewe, W., & Brooks, D. (2018) · Movement Disorders · doi:10.1002/mds.27386 · Cited by 121
The Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-Analysis
Hong, C. T., Chan, L., & Bai, C.-H. (2020) · Nutrients · doi:10.3390/nu12061860 · Cited by 113
Dopamine-dependent motor learning: insight into levodopa's long-duration response
Beeler, J. A., Cao, Z. F. H., Kheirbek, M. A., Ding, Y., Koranda, J., Murakami, M., Kang, U. J., & Zhuang, X. (2010) · Annals of Neurology · doi:10.1002/ana.21947 · Cited by 104
Christine, C. W., Richardson, R. M., Van Laar, A. D., Thompson, M. E., Fine, E. M., Khwaja, O. S., Li, C., Liang, G. S., Meier, A., Roberts, E. W., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000012952 · Cited by 89
Targeting the Progression of Parkinsons Disease
George, J., Mok, S., Moses, D., Wilkins, S., Bush, A., Cherny, R., & Finkelstein, D. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602814 · Cited by 77
Herzog, C. D., Dass, B., Gasmi, M., Bakay, R., Stansell, J. E., Tuszynski, M., Bankiewicz, K., Chen, E.-Y., Chu, Y., Bishop, K., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.170 · Cited by 72
Jokinen, P., Helenius, H., Rauhala, E., Brück, A., Eskola, O., & Rinne, J. O. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.061572 · Cited by 72
Zhao, Y., Zhang, Z., Qin, S., Fan, W., Li, W., Liu, J., Wang, S., Xu, Z., & Zhao, M. (2021) · Neural Plasticity · doi:10.1155/2021/9926445 · Cited by 68
How do you treat motor complications in Parkinson's disease: medicine, surgery, or both?
Fahn, S. (2009) · Annals of Neurology · doi:10.1002/ana.21453 · Cited by 66
Stacy, M. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0424-5 · Cited by 66
Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease
Poewe, W., & Mahlknecht, P. (2020) · Neurologic Clinics · doi:10.1016/j.ncl.2019.12.002 · Cited by 60
Lee, C.-H., & Hung, S.-Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010031 · Cited by 50
Mazzocchi, M., Goulding, S. R., Morales-Prieto, N., Foley, T., Collins, L. M., Sullivan, A. M., & O'Keeffe, G. W. (2022) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.02.025 · Cited by 32
Terashi, H., Mitoma, H., Yoneyama, M., & Aizawa, H. (2017) · Applied Sciences · doi:10.3390/app7050486 · Cited by 8
Metadata
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-12-09
- Volume
- 351
- Issue
- 24
- Pages
- 2498-2508
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1533056363
- Cited by
- 1,821
- References
- 33
- FWCI
- 43.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.